Earnings Call · Q4 FY2023·2024-03-14

Q4 23EPS +4.44%·Rev n/aQ3 23EPS +28.85%·Rev n/aQ2 23EPS +10.17%·Rev n/aQ1 23EPS -9.68%·Rev n/a⚠ consensus missing

Allogene Therapeutics, Inc. ALLO

Christine Cassiano — Investor Relations or Communications

David Chang — Chief Executive Officer (CEO)

Zachary Roberts — Executive or Senior Management (likely Chief Medical Officer or similar)

Geoff Parker — Executive or Senior Management

+3.7%1d on move date+4.4% vs SPY3d−2.3%5d−2.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALLO calls or request research access.

More ALLO calls Browse calls Request research access